SEARCH

SEARCH BY CITATION

References

  • Aicardi J, Mumford J, Dumas C, Wood S. (1996) Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia. 37:638642.
  • Appleton R, Peters AC, Mumford JP, Shaw DE. (1999) Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia. 40:16271633.
  • Bekiesinska-Figatowska M, Walecki J, Wagiel K, Jurkiewicz E. (2001) MRI in the diagnosis of congenital white matter diseases and other neurodegenerative diseases. Neurol Neurochir Pol 35:605619.
  • Ben-Menachem E, Nordborg C, Hedstrom A, Augustinsson LE, Silvenius H. (1988) Case report of surgical brain sample after 2.5 years of vigabatrin therapy [abstract]. Epilepsia. 29(suppl 5):699.
  • Bruni J, Guberman A, Vachon L, Desforges C. (2000) Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure. 9:224232.
  • Bryant A, Lopes MB, Bebin EM. (1994) Absence of intramyelinic edema in three patients treated with vigabatrin [abstract]. Epilepsia. 35(suppl 8):115.
  • Cannon D, Weller RO, Mumford JP. (1991a) No vigabatrin-induced microvacuolization in human brains: further neuropathological investigations [abstract]. Epilepsia. 32(suppl 1):12.
  • Cannon DJ, Butler WH, Mumford JP, Lewis PJ. (1991b) Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol (suppl 2):S17S24.
  • Chiron C, Dulac O, Luna D, Palacios L, Mondragon S, Beaumont D, Mumford JP. (1990) Vigabatrin in infantile spasms. Lancet 335:363364.
  • Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26:389395.
  • Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. (2000) The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 41:148157.
  • Cote CJ, Wilson S. (2006) Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics 118:25872602.
  • Desai NK, Runge VM, Crisp DE, Crisp MB, Naul LG. (2003) Magnetic resonance imaging of the brain in glutaric acidemia type I: a review of the literature and a report of four new cases with attention to the basal ganglia and imaging technique. Invest Radiol 38:489496.
  • Desguerre I, Pinton F, Nabbout R, Moutard ML, N’Guyen S, Marsac C, Ponsot G, Dulac O. (2003) Infantile spasms with basal ganglia MRI hypersignal may reveal mitochondrial disorder due to T8993G MT DNA mutation. Neuropediatrics 34:265269.
  • Desguerre I, Marti I, Valayannopoulos V, Bahi-Buisson N, Dulac O, Plouin P, Delonlay P, Hertz-Pannier L, Boddaert N. (2008) Transient magnetic resonance diffusion abnormalities in West syndrome: the radiological expression of non-convulsive status epilepticus? Dev Med Child Neurol 50:112116.
  • Elterman RD, Shields WD, Mansfield KA, Nakagawa J. (2001) Randomized trial of vigabatrin in patients with infantile spasms. Neurology 57:14161421.
  • French JA, Mosier M, Walker S, Sommerville K, Sussman N. (1996) A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 46:5461.
  • Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW. (1990) Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 18:225238.
  • Guberman A, Bruni J. (2000) Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 9:112118.
  • Hammond EJ, Ballinger WE Jr, Lu L, Wilder BJ, Uthman BM, Reid SA. (1992) Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy. Epilepsy Res 12:261265.
  • Horvath R, Abicht A, Holinski-Feder E, Laner A, Gempel K, Prokisch H, Lochmuller H, Klopstock T, Jaksch M. (2006) Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J Neurol Neurosurg Psychiatry 77:7476.
  • Jackson GD, Williams SR, Weller RO, Van Bruggen N, Preece NE, Williams SC, Butler WH, Duncan JS. (1994) Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 18:5766.
  • Lippert B, Metcalf BW, Jung MJ, Casara P. (1977) 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur J Biochem 74:441445.
  • Oster J, Doherty C, Grant PE, Simon M, Cole AJ. (2003) Diffusion-weighted imaging abnormalities in the splenium after seizures. Epilepsia 44:852854.
  • Paljarvi L, Vapalahti M, Sivenius J, Riekkinen P. (1990) Neuropathological findings in 5 patients with vigabatrin treatment [abstract]. Neurology 40(suppl 1):157.
  • Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM. (2003) Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 54(suppl 6):S73S80.
  • Pearl P, Molloy-Wells E, McClintock WM, Vezina LG, Conry JA, Elling NJ, Tsuchida T, Heath C, Cushner-Weinstein S, Kolodgie M, Weinstein SL, Gaillard WD. (2006) MRI abnormalities associated with vigabatrin therapy: higher risk in infants? Epilepsia 47(suppl 4):14.
  • Pedersen B, Hojgaard K, Dam M. (1987) Vigabatrin: no microvacuoles in a human brain. Epilepsy Res 1:7476.
  • Peyster RG, Sussman NM, Hershey BL, Heydorn WE, Meyerson LR, Yarrington JT, Gibson JP. (1995) Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 36:93100.
  • Preece NE, Houseman J, King MD, Weller RO, Williams SR. (2004) Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry. Synapse 53:3643.
  • Sander JW, Trevisol-Bittencourt PC, Hart YM, Shorvon SD. (1990) Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry 53:10081010.
  • Urbach H. (2005) Imaging of the epilepsies. Eur Radiol 15:494500.
  • Weiss KL, Schroeder CE, Kastin SJ, Gibson JP, Yarrington JT, Heydorn WE, McBride RG, Sussman NM, Arezzo JC. (1994) MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology 44:19441949.
  • Wohlrab G, Boltshauser E, Schmitt B. (1998) Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome. Neuropediatrics 29:133136.
  • Yarrington JT, Gibson JP, Dillberger JE, Hurst G, Lippert B, Sussman NM, Heydorn WE, Marler RJ. (1993) Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 21:480489.
  • Ziyeh S, Berlis A, Korinthenberg R, Spreer J, Schumacher M. (2002) Selective involvement of the globus pallidus and dentate nucleus in succinic semialdehyde dehydrogenase deficiency. Pediatr Radiol 32:598600.